Related references
Note: Only part of the references are listed.Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2022)
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2021)
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2021)
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology
David S. Shulman et al.
CANCER MEDICINE (2021)
Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival
AnnaLynn M. Williams et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence
Mark W. Kieran et al.
PEDIATRIC BLOOD & CANCER (2021)
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Gilles Vassal et al.
MOLECULAR CANCER THERAPEUTICS (2021)
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
Andrew D. J. Pearso et al.
EUROPEAN JOURNAL OF CANCER (2020)
Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades
Jennifer M. Yeh et al.
JAMA ONCOLOGY (2020)
Expanded Access as a source of real-world data: An overview of FDA and EMA approvals
Tobias B. Polak et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups
Elke Pfaff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Can a Multistakeholder Prioritization Structure Support Regulatory Decision Making? A Review of Pediatric Oncology Strategy Forums Reflecting on Challenges and Opportunities of this Concept
Dominik Karres et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center
Mir Lim et al.
CANCER MEDICINE (2020)
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew. D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2020)
Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration
Gregory Reaman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
Marie Wong et al.
NATURE MEDICINE (2020)
Terry Fox PRecision Oncology For Young peopLE (PROFYLE): A Canadian precision medicine program for children, adolescents and young adults with hard-to-treat cancer
Stephanie A. Grover et al.
CANCER RESEARCH (2020)
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2020)
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Timing of first-in-child trials of FDA-approved oncology drugs
Dylan Neel et al.
EUROPEAN JOURNAL OF CANCER (2019)
Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.
Pablo Berlanga et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors
Mark W. Kieran et al.
CLINICAL CANCER RESEARCH (2019)
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations
Sally L. George et al.
EUROPEAN JOURNAL OF CANCER (2019)
Physician perspectives on compassionate use in pediatric oncology
Scott Moerdler et al.
PEDIATRIC BLOOD & CANCER (2019)
Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE
N. Gaspar et al.
ANNALS OF ONCOLOGY (2018)
10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2018)
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
Franco Locatelli et al.
LANCET HAEMATOLOGY (2018)
Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents
Meredith K. Chuk et al.
CLINICAL CANCER RESEARCH (2017)
Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer
Gilles Vassal et al.
EUROPEAN JOURNAL OF CANCER (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
From class waivers to precision medicine in paediatric oncology
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Pediatric oncology enters an era of precision medicine
Nita L. Seibel et al.
CURRENT PROBLEMS IN CANCER (2017)
Implementation of mechanism of action biology-driven early drug development for children with cancer
Andrew D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2016)
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study
Barbara C. Worst et al.
EUROPEAN JOURNAL OF CANCER (2016)
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study
Marian H. Harris et al.
JAMA ONCOLOGY (2016)
Improving the outcome for children with cancer: Development of targeted new agents
Peter C. Adamson
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer
Gilles Vassal et al.
EUROPEAN JOURNAL OF CANCER (2015)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
Challenging issues in pediatric oncology
Ching-Hon Pui et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The role of the 'innovative therapies for children with cancer' (ITCC) European consortium
C. Michel Zwaan et al.
CANCER TREATMENT REVIEWS (2010)
Pediatric phase I trials in oncology: An analysis of study conduct efficiency
DP Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
